{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T03:21:21Z","timestamp":1787541681904,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011772","name":"Novartis Farmac\u00e9utica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011772","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015068","name":"Universidade de Santiago de Compostela","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100015068","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Peptide receptor radionuclide therapy (PRRT) is an established treatment for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors (SSTR). Despite robust trial and real-world data, heterogeneity persists regarding patient selection, therapeutic sequencing, and follow-up strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Delphi consensus was conducted by the Galician Multidisciplinary Group on Neuroendocrine and Endocrine Tumors (GGNET). Ten experts in oncology, endocrinology, nuclear medicine, and radiology participated. 29 clinical statements were developed after a systematic review and rated using a 4-point Likert scale. Consensus was defined as \u2265\u200970% agreement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Consensus (defined a priori as \u2265\u200970% agreement) was achieved for all statements although the level of agreement varied across domains. PRRT was endorsed for patients with unresectable or metastatic, progressive, well-differentiated GEP-NETs (grades 1\u20133, Ki-67 \u2264\u200955%) with confirmed SSTR expression. SSTR-targeted imaging (PET or scintigraphy) was considered mandatory for eligibility, with PET identified as the preferred modality. [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FDG-PET was recommended selectively as a complementary prognostic tool in higher-grade tumors, rapid progression, or discordant imaging. Multidisciplinary tumor board review was universally supported. Guidance was provided on treatment administration, including standard dosing, renal protection, hematologic monitoring, and individualized risk assessment. Routine interim imaging was not recommended. Structured follow-up with CT\/MRI was endorsed, with indication-driven use of SSTR or FDG-PET and limited routine value of non-specific biomarkers. Functional biomarkers, such as 5-HIAA and peptide hormones, retained utility in functioning tumors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This Delphi consensus provides pragmatic, multidisciplinary, and evidence-informed guidance to harmonize routine clinical practice in the use of PRRT for well-differentiated, SSTR-positive NETs. The proposed statements and the algorithm aim to harmonize practice across centers, reduce variability in care, enhance safety, and ultimately improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-026-04226-7","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T10:25:34Z","timestamp":1773138334000},"page":"4139-4149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recommendations for selection, treatment, and follow-up in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors: a Delphi consensus from the Galician Multidisciplinary Group on Neuroendocrine and Endocrine Tumors (GGNET)"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0408-6871","authenticated-orcid":false,"given":"Nieves","family":"Martinez-Lago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Cabezas Agricola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urbano","family":"Anido Herranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulema","family":"Nogareda Seoane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00eda","family":"Cousillas Casti\u00f1eiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Varela Ponte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Fern\u00e1ndez Catalina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estephany","family":"Abou Jokh Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"de Mat\u00edas Leralta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Pubul Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"10","key":"4226_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589.","journal-title":"JAMA Oncol"},{"issue":"1","key":"4226_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115\u201354. https:\/\/doi.org\/10.1007\/s12022-022-09708-2.","journal-title":"Endocr Pathol"},{"issue":"6","key":"4226_CR3","doi-asserted-by":"publisher","first-page":"R163","DOI":"10.1530\/ERC-19-0437","volume":"27","author":"G Gaudenzi","year":"2020","unstructured":"Gaudenzi G, Carra S, Dicitore A, Cantone MC, Persani L, Vitale G. Fishing for neuroendocrine tumors. Endocr Relat Cancer. 2020;27(6):R163\u201376. https:\/\/doi.org\/10.1530\/ERC-19-0437.","journal-title":"Endocr Relat Cancer"},{"issue":"15","key":"4226_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12155138","volume":"12","author":"Q Sultana","year":"2023","unstructured":"Sultana Q, Kar J, Verma A, Sanghvi S, Kaka N, Patel N, et al. A comprehensive review on neuroendocrine neoplasms: presentation, pathophysiology and management. J Clin Med. 2023;12(15):5138. https:\/\/doi.org\/10.3390\/jcm12155138.","journal-title":"J Clin Med"},{"issue":"7","key":"4226_CR5","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844\u201360. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.304.","journal-title":"Ann Oncol"},{"issue":"28","key":"4226_CR6","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, M\u00fcller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID). J Clin Oncol. 2009;27(28):4656\u201363. https:\/\/doi.org\/10.1200\/JCO.2009.22.8510.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4226_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB, Phan AT, Raderer M, Sedl\u00e1\u010dkov\u00e1 E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1316158.","journal-title":"N Engl J Med"},{"issue":"2","key":"4226_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"issue":"10433","key":"4226_CR9","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for newly diagnosed, advanced grade 2\u20133 well-differentiated gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403(10433):2807\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(24)00701-3.","journal-title":"Lancet"},{"key":"4226_CR10","unstructured":"Capdevila J, Amthauer H, Ansquer C, Deshayes E, Garcia-Carbonero R, Teul\u00e9 Vega A, et al. Efficacy and safety of [177Lu]Lu-edotreotide vs. everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE phase 3 trial. In: 22nd Annual ENETS conference; 2025 Mar 5\u20137; Krakow, Poland. Abstract #4669."},{"key":"4226_CR11","unstructured":"Baudin E, Walter T, Beron A, Smith D, Deandreis D, Ta\u00efeb D, et al. Secondary endpoint results of the first multicentric randomised phase II trial investigating the antitumour efficacy of 177Lu-DOTA-Octreotate (OCLU) in advanced progressive pancreatic NET: the OCLURANDOM trial. In: 22nd Annual ENETS conference; 2025 Mar 5\u20137; Krakow, Poland. Abstract #4562."},{"issue":"16","key":"4226_CR12","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2743.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"4226_CR13","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1007\/s00259-023-06166-8","volume":"50","author":"M Mitjavila","year":"2023","unstructured":"Mitjavila M, Jimenez-Fonseca P, Bell\u00f3 P, Pubul V, Percovich JC, Garcia-Burillo A, et al. Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study. Eur J Nucl Med Mol Imaging. 2023;50(8):2486\u2013500. https:\/\/doi.org\/10.1007\/s00259-023-06166-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4226_CR14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.25.00791","author":"FI Lin","year":"2025","unstructured":"Lin FI, Del Rivero J, Carrasquillo JA, Jha A, Zou J, Shamis I, et al. Phase II study of 177Lu-DOTATATE for progressive metastatic pheochromocytomas and paragangliomas: interim analysis of efficacy, safety, and biomarkers. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO.25.00791.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4226_CR15","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s00259-016-3328-2","volume":"43","author":"B Nilica","year":"2016","unstructured":"Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, et al. Direct comparison of 68Ga-DOTA-TOC and 18F-FDG PET\/CT in the follow-up of patients with neuroendocrine tumour treated with the first full cycle of PRRT. Eur J Nucl Med Mol Imaging. 2016;43(9):1585\u201392. https:\/\/doi.org\/10.1007\/s00259-016-3328-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"4226_CR16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1148\/rg.352140164","volume":"35","author":"MS Hofman","year":"2015","unstructured":"Hofman MS, Lau WFE, Hicks RJ. Somatostatin receptor imaging with 68Ga-DOTATATE PET\/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35(2):500\u201316. https:\/\/doi.org\/10.1148\/rg.352140164.","journal-title":"Radiographics"},{"issue":"12","key":"4226_CR17","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. Final overall survival and long-term safety results from NETTER-1, an open-label, randomized, phase 3 trial of [177Lu]Lu-DOTATATE in patients with midgut neuroendocrine tumors. Lancet Oncol. 2021;22(12):1752\u201363. https:\/\/doi.org\/10.1016\/S1470-2045(21)00572-6.","journal-title":"Lancet Oncol"},{"key":"4226_CR18","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 1.2023. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine.pdf. Accessed 15 Sep 2025."},{"issue":"6","key":"4226_CR19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.2967\/jnumed.115.165803","volume":"57","author":"SA Deppen","year":"2016","unstructured":"Deppen SA, Blume J, Bobbey AJ, Shah C, Graham MM, Lee P, et al. 68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. J Nucl Med. 2016;57(6):872\u20138. https:\/\/doi.org\/10.2967\/jnumed.115.165803.","journal-title":"J Nucl Med"},{"issue":"10","key":"4226_CR20","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2967\/jnumed.120.256727","volume":"62","author":"C Ortega","year":"2021","unstructured":"Ortega C, Wong RKS, Schaefferkoetter J, Veit-Haibach P, Myrehaug S, Juergens R, et al. Quantitative 68Ga-DOTATATE PET\/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with 177Lu-DOTATATE. J Nucl Med. 2021;62(10):1406\u201314. https:\/\/doi.org\/10.2967\/jnumed.120.256727.","journal-title":"J Nucl Med"},{"issue":"5","key":"4226_CR21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.2967\/jnumed.116.185587","volume":"58","author":"M Barrio","year":"2017","unstructured":"Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, Du L, et al. The impact of somatostatin receptor-directed PET\/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis. J Nucl Med. 2017;58(5):756\u201361. https:\/\/doi.org\/10.2967\/jnumed.116.185587.","journal-title":"J Nucl Med"},{"key":"4226_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194836","volume":"15","author":"TR Halfdanarson","year":"2023","unstructured":"Halfdanarson TR, Mallak N, Paulson S, Chandrasekharan C, Natwa M, Kendi AT, et al. Monitoring and surveillance of patients with gastroenteropancreatic neuroendocrine tumors undergoing radioligand therapy. Cancers. 2023;15:4836. https:\/\/doi.org\/10.3390\/cancers15194836.","journal-title":"Cancers"},{"key":"4226_CR23","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2967\/jnumed.118.230607","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, et al. NANETS\/SNMMI procedure standard for somatostatin receptor-based PRRT with 177Lu-DOTATATE. J Nucl Med. 2019;60:937\u201343. https:\/\/doi.org\/10.2967\/jnumed.118.230607.","journal-title":"J Nucl Med"},{"key":"4226_CR24","unstructured":"Norman AP, Wee C, Hobday TJ, Kendi AT, Johnson GB, Thorpe MP, et al. Utility of midpoint imaging in patients receiving PRRT for progressive GEP-NETs. In: NANETS 2021 symposium abstracts."},{"issue":"5","key":"4226_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1530\/ERC-16-0524","volume":"24","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, de Herder WW, Feelders RA, et al. Pitfalls in response evaluation after PRRT with [177Lu]Lu-DOTATATE. Endocr Relat Cancer. 2017;24(5):243\u201351. https:\/\/doi.org\/10.1530\/ERC-16-0524.","journal-title":"Endocr Relat Cancer"},{"key":"4226_CR26","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2214\/AJR.21.27159","volume":"218","author":"SJ Galgano","year":"2022","unstructured":"Galgano SJ, Iravani A, Bodei L, El-Haddad G, Hofman MS, Kong G. Imaging of neuroendocrine neoplasms: monitoring treatment response\u2014AJR expert panel narrative review. AJR Am J Roentgenol. 2022;218:767\u201380. https:\/\/doi.org\/10.2214\/AJR.21.27159.","journal-title":"AJR Am J Roentgenol"},{"issue":"13","key":"4226_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13132154","volume":"13","author":"A Adnan","year":"2023","unstructured":"Adnan A, Basu S. Somatostatin receptor targeted PET-CT and its role in the management and theranostics of gastroenteropancreatic neuroendocrine neoplasms. Diagnostics (Basel). 2023;13(13):2154. https:\/\/doi.org\/10.3390\/diagnostics13132154.","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"4226_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40644-020-00335-w","volume":"20","author":"DMV Huizing","year":"2020","unstructured":"Huizing DMV, Aalbersberg EA, Versleijem MWJ, Tesselaar MET, Walraven I, Lahaye MJ, et al. Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy. Cancer Imaging. 2020;20(1):57. https:\/\/doi.org\/10.1186\/s40644-020-00335-w.","journal-title":"Cancer Imaging"},{"issue":"12","key":"4226_CR29","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.2967\/jnumed.120.257808","volume":"61","author":"TA Hope","year":"2020","unstructured":"Hope TA. Updates to the appropriate-use criteria for somatostatin receptor PET. J Nucl Med. 2020;61(12):1764. https:\/\/doi.org\/10.2967\/jnumed.120.257808.","journal-title":"J Nucl Med"},{"issue":"6","key":"4226_CR30","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","volume":"46","author":"JR Strosberg","year":"2017","unstructured":"Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, et al. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas. 2017;46(6):707\u201314. https:\/\/doi.org\/10.1097\/MPA.0000000000000850.","journal-title":"Pancreas"},{"issue":"7","key":"4226_CR31","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1097\/MPA.0000000000001597","volume":"49","author":"TR Halfdanarson","year":"2020","unstructured":"Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O\u2019Dorisio TM, et al. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49(7):863\u201381. https:\/\/doi.org\/10.1097\/MPA.0000000000001597.","journal-title":"Pancreas"},{"issue":"12","key":"4226_CR32","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.2217\/fon-2018-0960","volume":"15","author":"VN Joish","year":"2019","unstructured":"Joish VN, Shah S, Tierce JC, Patel D, McKee C, Lapuerta P, et al. Serotonin levels and 1-year mortality in patients with neuroendocrine tumors: a systematic review and meta-analysis. Future Oncol. 2019;15(12):1397\u2013406. https:\/\/doi.org\/10.2217\/fon-2018-0960.","journal-title":"Future Oncol"},{"issue":"46","key":"4226_CR33","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036094","volume":"102","author":"Y Alshareefy","year":"2023","unstructured":"Alshareefy Y, Cummins S, Mazzoleni A, Sharma V, Guggilapu S, Leong AWY, et al. A review of functional pancreatic neuroendocrine tumors: exploring the molecular pathogenesis, diagnosis and treatment. Medicine Baltimore. 2023;102(46):e36094. https:\/\/doi.org\/10.1097\/MD.0000000000036094.","journal-title":"Medicine Baltimore"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04226-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04226-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04226-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T03:09:10Z","timestamp":1787540950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04226-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["4226"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04226-7","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that they have no conflicts of interest related to this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The analysis in this article does not involve any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since the present consensus did not involve the participation of patients, informed consent was not deemed necessary.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}